Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✔).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. _____
(Online)
(Signature of healthcare professional)

First Name		Profession	
Surname		Telephone	
HPC No.		City	
E-mail			

1. The objectives of osteoporosis therapy are to:

- ☐ **A** Improve bone strength
- ☐ **B** Reduce risk of fracture
- ☐ **C** Prevent rapid bone loss
- ☐ **D** All of the above
- ☐ **E** A and B
- ☐ **F** A and C

2. Osteoporotic patients at very high risk for fracture include those with:

- ☐ **A** A fracture within the past year
- ☐ **B** Multiple fractures
- ☐ **C** A fracture while on osteoporosis treatment
- ☐ **D** A fracture while on medication harmful to bone
- ☐ **E** All of the above
- ☐ **F** B, C and D

3. Most guidelines recommend bisphosphonates as the preferred first-line treatment for patients at very high risk for fracture, followed by anabolic agents:

- ☐ **A** True
- ☐ **B** False

4. Under which circumstances is anabolic therapy recommended as second-line treatment for osteoporosis?

- ☐ **A** New fracture on current osteoporosis treatment
- ☐ **B** Unacceptable rates of bone loss following compliance with appropriate antiresorptive therapy
- ☐ **C** Chronic glucocorticosteroid therapy
- ☐ **D** All of the above
- ☐ **E** A and B
- ☐ **F** B and C

5. The anabolic effects of teriparatide result in an increase in:

- ☐ **A** Total bone volume
- ☐ **B** Periosteal diameter
- ☐ **C** Cortical thickness
- ☐ **D** Endocortical diameter
- ☐ **E** All of the above
- ☐ **F** A, B and C
- ☐ **G** A, C and D

6. From the VERO study, which statement is incorrect?

- ☐ **A** Teriparatide was compared to risedronate at 24 months of treatment in postmenopausal women who had severe osteoporosis
- ☐ **B** Of the study cohort, >70% had prior osteoporosis therapy
- ☐ **C** Previous bisphosphonate therapy precludes the use of teriparatide

7. Abaloparatide is a:

- ☐ **A** Selective oestrogen receptor modulator
- ☐ **B** An analogue of human PTHrP
- ☐ **C** A sclerostin inhibitor

8. From the ACTIVE trial, at 18 months of treatment with abaloparatide, new vertebral fractures were reduced by __%?

- ☐ **A** 65%
- ☐ **B** 80%
- ☐ **C** 86%

9. Sclerostin is a protein that is released by the osteocytes, generally in response to oestrogen deficiency, lack of skeletal loading and glucocorticoids:

- ☐ **A** True
- ☐ **B** False

10. From the ARCH study, hip fractures were reduced by approximately __% at 24 months of treatment with romosozumab?

- ☐ **A** 12%
- ☐ **B** 20%
- ☐ **C** 40%